Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
VVOS vs TPST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
TPST Captures Overall Composite Edge (39.2 SELL vs 36.4 SELL), While VVOS Leads 3–2 on Growth & Valuation Pillars
TPST Overall Winner
6-Pillar Tally: VVOS 3 – 2 TPST (1 Tie)
Matrix Metrics: VVOS 1 – 5 TPST
As of Nov 20, 2026, Tempest Therapeutics, Inc. (TPST) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (39.2/100 SELL vs. 36.4/100 SELL) after splitting the core matrix 5–1 (led by Profitability & Quality, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. VVOS trades at $0.05 (N/M Forward P/E, -107.9% operating margin) versus TPST at $0.29 (N/M Forward P/E, 0.0% operating margin).
- Growth vs. Quality Trade-Off: TPST earns the overall head-to-head edge with a stronger Unified Composite Score (39.2/100 SELL vs. VVOS 36.4/100 SELL) and 0.77β · 85% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Defensive Composite Rating Caution: Although TPST compares more favorably head-to-head, both VVOS (36.4/100 SELL) and TPST (39.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
- Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile TPST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About VVOS vs TPST
VVOS
Vivos Therapeutics, Inc. Common Stock
$0.05
-5.1% 1D
Market Cap
$1.9M
TTM Revenue
$21M
Forward P/E
N/M
Beta / 30D Vol
1.70β · 111% Vol
Unified Composite Score
36.4
SELL
Tech 25.0
Fund 35.0
Flow 50.0
Mom 30.0
Weinstein Technical Phase
Markdown · Sell / avoid
TPST
Head-to-Head Winner
Tempest Therapeutics, Inc. Common Stock
$0.29
-6.18% 1D
Market Cap
$6.1M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.77β · 85% Vol
Unified Composite Score
39.2
SELL
Tech 25.0
Fund 44.0
Flow 50.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (VVOS 3 – 2 TPST)
1. Valuation Multiples
VVOS
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.1x
N/M
2. Growth & Scale
VVOS
Revenue Growth (YoY)
+34.9%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$21M
N/A
Market Cap
$1.9M
$6.1M
3. Profitability & Quality
TPST
Gross Margin
61.9%
N/A
Operating Margin
-107.9%
0.0%
Net Profit Margin
-121.8%
0.0%
Return on Equity (ROE)
-8585.3%
-1797.6%
4. Balance Sheet & Cash Flow
VVOS
Cash Generation (TTM)
-$21M EBITDA
N/A
Cash Flow Margin
-99.3% EBITDA Mgn
N/A
Net Cash / Leverage
-8585.3% ROE
$6.8M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
TPST
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: VVOS (1) vs TPST (5)| Institutional Metric | VVOS | TPST | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.9M | $6.1M | Tie | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +34.9% | +0.0% | VVOS | |
| Operating Margin (TTM) | -107.9% | 0.0% | TPST | |
| Net Profit Margin | -121.8% | 0.0% | TPST | |
| Return on Equity (ROE) | -8585.3% | -1797.6% | TPST | |
| 52-Week Range Position | 0% ($0–$3) | 0% ($0–$9) | Tie | |
| Beta / 30D Volatility | 1.70β · 111% Vol | 0.77β · 85% Vol | TPST | |
| Unified Institutional Score | 36.4 / 100 (SELL) | 39.2 / 100 (SELL) | TPST | |
| Trailing 12M Revenue (USD) | $21M | N/A | Scale | |
| Gross Profit Margin (TTM) | 61.9% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.1x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$21M EBITDA (-8585.3% ROE) | N/A ($6.8M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
TPST +14.2 pp
3M Horizon
TPST +6.58 pp
6M Horizon
TPST +6.58 pp
1Y Horizon
TPST +3.75 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VVOS Revenue | TPST Revenue | VVOS Op. Margin | TPST Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2017 | N/A | $0M | N/A | -28585.1% | TPST |
| FY2019 | $10M | N/A | -92.8% | N/A | VVOS |
| FY2020 | $10M | N/A | -92.1% | N/A | VVOS |
| FY2021 | $20M | N/A | -120.7% | N/A | VVOS |
| FY2022 | $20M | N/A | -156.2% | N/A | VVOS |
| FY2023 | $10M | N/A | -125.3% | N/A | VVOS |
| FY2024 | $20M | N/A | -74.3% | N/A | VVOS |
| FY2025 | $20M | N/A | -114.1% | N/A | VVOS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
VVOS
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
TPST
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact TPST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
VVOS Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
TPST Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ VVOS vs TPST Key Questions & Quantitative Answers
As of Nov 20, 2026, Tempest Therapeutics, Inc. (TPST) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (39.2/100 SELL vs. 36.4/100 SELL) after splitting the core matrix 5–1 (led by Profitability & Quality, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. VVOS trades at $0.05 (N/M Forward P/E, -107.9% operating margin) versus TPST at $0.29 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: TPST earns the overall head-to-head edge with a stronger Unified Composite Score (39.2/100 SELL vs. VVOS 36.4/100 SELL) and 0.77β · 85% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although TPST compares more favorably head-to-head, both VVOS (36.4/100 SELL) and TPST (39.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile TPST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VVOS leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with TPST at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), VVOS cumulative revenue shifted +100.0% while TPST shifted N/A. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TPST.
VVOS screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas TPST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus TPST (-1797.6% ROE) capital efficiency.
In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, TPST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.77β · 85% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
TPST vs VVOS · Reverse Pair
TPST vs AVTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal